Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455614 | 0.81 | MAPT (0.51) | MAPTKMT2AUSP2NPSR1ESR1 | |
| SCHEMBL2447185 | 0.79 | MAPT (0.55) | MAPTKMT2AUSP2NPSR1ESR1 | |
| Hydrochloric Acid SCHEMBL27471658 | 0.79 | ALDH1A1 (0.52) | MAPTKMT2AUSP2NPSR1ESR1 | |
| Hydrochloric Acid SCHEMBL17871734 | 0.76 | ALDH1A1 (0.53) | MAPTKMT2AUSP2NPSR1ESR1 | |
| SCHEMBL10349010 | 0.76 | ALDH1A1 (0.47) | MAPTKMT2AUSP2NPSR1ALDH1A1 | |
| SCHEMBL5487545 | 0.75 | CHRNA7 (0.44) | MAPTALDH1A1L3MBTL1TSHRKCNQ2 | |
| SCHEMBL18228234 | 0.75 | L3MBTL1 (0.61) | MAPTKMT2AUSP2NPSR1ALDH1A1 | |
| SCHEMBL12485 | 0.75 | L3MBTL1 (0.61) | MAPTKMT2AUSP2NPSR1ALDH1A1 | |
| SCHEMBL127629 | 0.74 | IDO1 (0.46) | ESR1TSHRLMNASMN1; SMN2KDM4E | |
| SCHEMBL5792650 | 0.73 | LMNA (0.55) | MAPTKMT2AUSP2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240557-B | Pyrrolidine amide derivatives and use thereof | 广东东阳光药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-10702479-B2 | Pharmaceutical formulation comprising sembragiline | HOFFMANN-LA ROCHE INC. (US) | 2020-07-07 | — | — | US | disclosed |
| CN-110240557-A | Pyrrolidine derivative and application thereof | 广东东阳光药业有限公司 | 2019-09-17 | — | — | CN | disclosed |
| US-20180042853-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | HOFFMANN-LA ROCHE INC. (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3273946-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | F. Hoffmann-La Roche AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2016156124-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-06 | — | — | WO | disclosed |
| EP-3063130-A1 | CRYSTALLINE FORMS OF A PYRROLIDONE DERIVATIVE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE AND PREPARATION THEREOF | F. Hoffmann-La Roche AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015063001-A1 | CRYSTALLINE FORMS OF A PYRROLIDONE DERIVATIVE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE AND PREPARATION THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2006097197-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097270-A1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| CN-1681779-A | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542971-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. Hoffmann-La Roche Ltd. (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-05-20 | — | — | US | disclosed |
| WO-2004026826-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702479-B2 | Pharmaceutical formulation comprising sembragiline | SLC6A11, SLC10A1, CYP3A7 | MAPT 98/4885KMT2A 990/4885USP2 4408/4885 |
| US-20180042853-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | SLC6A11, SLC10A1, CYP3A7 | MAPT 98/4885KMT2A 990/4885USP2 4408/4885 |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | MAPT 44/4885KMT2A 1205/4885USP2 2422/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | MAPT 156/4885KMT2A 606/4885USP2 1696/4885 |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | NANS, PFAS, ALDH18A1 | MAPT 2117/4885KMT2A 1348/4885USP2 2439/4885 |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | MAPT 51/4885KMT2A 1207/4885USP2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.